Current concepts in targeted therapies for benign tumors of the jaw—A review of the literature
N Graillon, SO Akintoye, O Iocca, A Kaleem… - Journal of Cranio …, 2023 - Elsevier
Benign odontogenic and maxillofacial bone tumors often require radical surgery, with
consequent morbidity that impacts patients' postsurgical quality of life. Currently, targeted …
consequent morbidity that impacts patients' postsurgical quality of life. Currently, targeted …
Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
N Li, P Lin, Z Zuo, MJ You, W Shuai… - Cancer …, 2023 - Wiley Online Library
BACKGROUND Mutations in the RAS‐MAPK pathway, such as KRAS, NRAS, and BRAF,
are known as high‐risk factors associated with poor prognosis in patients with various …
are known as high‐risk factors associated with poor prognosis in patients with various …
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study
C Quivoron, JM Michot, A Danu, H Lecourt… - Leukemia & …, 2024 - Taylor & Francis
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-
derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to …
derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to …
Precision medicine approach based on molecular alterations for patients with relapsed or refractory multiple myeloma: results from the MM-EP1 study
F Andreozzi, M Dragani, C Quivoron, F Le Bras, T Assi… - Cancers, 2023 - mdpi.com
Simple Summary Personalized treatment for patients with relapsed or refractory multiple
myeloma (r/r MM) remains an ongoing challenge, and there are no anti-myeloma therapies …
myeloma (r/r MM) remains an ongoing challenge, and there are no anti-myeloma therapies …
DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis
Simple Summary Multiple myeloma is a hematologic neoplasm caused by abnormalities of
plasma cells. Although cytogenetic-based risk stratifications are in clinical use, the role of …
plasma cells. Although cytogenetic-based risk stratifications are in clinical use, the role of …
Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patients
N Li, P Lin, Z Zuo, MJ You, W Shuai, RZ Orlowski… - 2022 - researchsquare.com
High-throughput genomic analysis of plasma cell myeloma has identified recurrent gene
mutations of prognostic significance. Mutations in the RAS-MAPK pathway, such as KRAS …
mutations of prognostic significance. Mutations in the RAS-MAPK pathway, such as KRAS …